Roche’s Actemra May Curb Deaths in Critical Covid Patients
5 years ago 1 min read
Roche Holding AG’s Actemra may help critically ill patients survive Covid-19, according to researchers who used a novel approach to show those who quickly got the anti-inflammatory medication were 30% less likely to die.
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push